Improved bone health and the subsequent reduction in fracture risk represents a significant health intervention, improving longevity as well as quality of life in aging populations. The development of ?anabolic? agents that can promote the rebuilding of lost bone mass would represent a significant impact on the field and on the treatment of bone disease. We have engineered a bio-active silica based nanoparticle capable of promoting osteoblast differentiation and mineralization while inhibiting osteoclastogenesis and therefore these nanoparticles have the potential to promote new bone formation while simultaneously reducing bone breakdown. The goals of this study are to further investigate these novel nanoparticles for the treatment of systemic bone disease. The studies proposed herein will test the hypothesis that engineered silica based nanoparticles represent a novel therapeutic agent capable of preventing and/or reversing bone loss in a pre- clinical model of post-menopausal bone loss. We will investigate the optimal method of administration as well as attempt to increase efficacy through bone targeting surface properties. Endpoints include a quantitation of nanoparticle absorption relevant to route of administration, quantitative and qualitative analysis of bone metabolism and serum markers. Additionally, we will utilize a reporter mouse to assess the possibility that the nanoparticles work in part by stimulation of autophagy.

Public Health Relevance

Loss of bone health can have serious health consequences including fracture which often requires lengthy rehabilitation, prolonged or permanent disability, and almost always require hospitalization with associated major surgery. We have engineered 50nm bioactive silica based nanoparticles that enhance the ability of bone forming osteoblasts while inhibiting bone resorbing osteoclasts. As such these nanoparticles represent a novel dual pro-anabolic-anti-catabolic compound and our goals are to optimize these particles for delivery, absorption, and improved efficacy by the addition of bone targeting surface properties.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AR073593-02
Application #
9850538
Study Section
Skeletal Biology Development and Disease Study Section (SBDD)
Program Officer
Nicks, Kristy
Project Start
2019-01-15
Project End
2020-12-31
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
2
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322